[{"address1": "IDA Business Park", "city": "Bray", "zip": "A98 H5C8", "country": "Ireland", "phone": "353 1 276 9800", "fax": "353 1 276 9888", "website": "https://www.trinitybiotech.com", "industry": "Medical Devices", "sector": "Healthcare", "longBusinessSummary": "Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.", "fullTimeEmployees": 380, "companyOfficers": [{"maxAge": 1, "name": "Mr. John  Gillard", "age": 42, "title": "President, CEO, Company Secretary & Director", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 710000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ronan  O'Caoimh", "age": 67, "title": "Founder, Director & Executive Advisor", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 80000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Walsh Ph.D.", "age": 65, "title": "Executive Director of Business Development & Executive Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 50000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Tallon", "title": "CFO & Chief Accounting Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jacqueline  O'Neill", "age": 50, "title": "Director of Operations", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary  Keating Ph.D.", "age": 50, "title": "Chief Technology Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Eibhlin  Kelly", "age": 39, "title": "Chief Information Officer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Colm  Molloy", "age": 52, "title": "Group Director of Human Resources & Culture", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adrian  Donohue", "title": "Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.685, "open": 1.69, "dayLow": 1.6516, "dayHigh": 1.82, "regularMarketPreviousClose": 1.685, "regularMarketOpen": 1.69, "regularMarketDayLow": 1.6516, "regularMarketDayHigh": 1.82, "exDividendDate": 1433462400, "fiveYearAvgDividendYield": 1.19, "beta": 1.198, "forwardPE": -1.7281554, "volume": 82505, "regularMarketVolume": 82505, "averageVolume": 1346695, "averageVolume10days": 212470, "averageDailyVolume10Day": 212470, "bid": 1.77, "ask": 1.83, "bidSize": 200, "askSize": 100, "marketCap": 16848608, "fiftyTwoWeekLow": 1.05, "fiftyTwoWeekHigh": 3.55, "priceToSalesTrailing12Months": 0.287264, "fiftyDayAverage": 1.819, "twoHundredDayAverage": 2.1403, "currency": "USD", "enterpriseValue": 424989792, "profitMargins": -0.38012, "floatShares": 95898767, "sharesOutstanding": 9465510, "sharesShort": 100040, "sharesShortPriorMonth": 213228, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0106, "heldPercentInsiders": 0.19681999, "heldPercentInstitutions": 0.23826, "shortRatio": 0.4, "shortPercentOfFloat": 0.025799999, "bookValue": -3.106, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -22291000, "trailingEps": -2.84, "forwardEps": -1.03, "pegRatio": -0.06, "lastSplitFactor": "1:4", "lastSplitDate": 1117670400, "enterpriseToRevenue": 7.246, "enterpriseToEbitda": -37.62, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TRIB", "underlyingSymbol": "TRIB", "shortName": "Trinity Biotech plc", "longName": "Trinity Biotech plc", "firstTradeDateEpochUtc": 719674200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f11095f5-a45d-3fd0-867a-c30f29ce8486", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.78, "recommendationKey": "none", "totalCash": 5317000, "totalCashPerShare": 0.028, "ebitda": -11297000, "totalDebt": 93335000, "quickRatio": 0.894, "currentRatio": 1.784, "totalRevenue": 58652000, "revenuePerShare": 6.968, "returnOnAssets": -0.09641, "freeCashflow": -9930875, "operatingCashflow": -8341000, "revenueGrowth": 0.14, "grossMargins": 0.34275, "ebitdaMargins": -0.19261, "operatingMargins": -0.105220005, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-17"}]